

BRAINSTORM CELL THERAPEUTICS INC  
Form 8-K  
August 03, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 2, 2010

Brainstorm Cell Therapeutics Inc.  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	333-61610 (Commission File No.)	20-8133057 (IRS Employer Identification No.)
---	------------------------------------	---

110 East 59 th Street New York, New York (Address of principal executive offices)	10022 (Zip Code)
---	---------------------

(212) 557-9000  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On August 2, 2010, Brainstorm Cell Therapeutics Inc. (the “Company”) announced that it intends to pursue a listing of Brainstorm Cell Therapeutics Ltd.’s securities on the Tel Aviv Stock Exchange. Brainstorm Cell Therapeutics Ltd. is a wholly-owned subsidiary of the Company. This Current Report on Form 8-K and the information disclosed herein is being filed pursuant to Rule 135c.

The securities of Brainstorm Cell Therapeutics Ltd. have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

August 3, 2010

Brainstorm Cell Therapeutics Inc.

By: /s/ Rami Efrati  
Rami Efrati  
Chief Executive Officer

---